KR850008282A - 그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법 - Google Patents

그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법 Download PDF

Info

Publication number
KR850008282A
KR850008282A KR1019850003622A KR850003622A KR850008282A KR 850008282 A KR850008282 A KR 850008282A KR 1019850003622 A KR1019850003622 A KR 1019850003622A KR 850003622 A KR850003622 A KR 850003622A KR 850008282 A KR850008282 A KR 850008282A
Authority
KR
South Korea
Prior art keywords
gram
human monoclonal
crl
negative
composition according
Prior art date
Application number
KR1019850003622A
Other languages
English (en)
Inventor
안토니 더블유(외 1) 시아닥
Original Assignee
원본미기재
제네틱 시스템스 코오포레이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24460190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850008282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 제네틱 시스템스 코오포레이숀 filed Critical 원본미기재
Publication of KR850008282A publication Critical patent/KR850008282A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y10S424/808—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 그람음성균의 막과 내벽의 설명도.
제2도는 리포다당류 분자의 구성도

Claims (13)

  1. 그람음성균의 접촉성의 리포다당류 분자상에서 혈청형 결정인자와 특성적으로 반응하는 인체 단크론항체.
  2. 그람음성균이 엔테로박테리아세, 박테로이다세 또는 슈도모나다세과의 한 멤버인 청구범위 1에 의거한 인체 단크론 항체.
  3. 적어도 두 인체 단크론 항체를 함유하는 조성물, 상기 단크론 항체의 각각은 다른 그람음성균의 리포다당류 분자상에서 혈청형 결정인자와 반응한다.
  4. 엔테로박테리아세, 박테로이다세 또는 슈도모나다세균과의 한혈청형 결정인자와 반응하는 인체 단크론항체인 청구범위 3에 의거한 조성물.
  5. 상기 단크론 항체가 동일한 균종의 다른 혈청형과 반응하는 청구범위 4에 따르는 조성물.
  6. 상기 종이 슈도모나스 에루기노자이며, 상기 항체가 피셔면역형 1내지 7의 적어도 2의 라포다당류와 반응하는 청구범위 5에 의거한 조성물.
  7. 청구범위 1,2,3,4,5 또는 6과 병리학적으로 허용되는 담체의 조성물로 구성되는 약학적 조성물.
  8. 그람음성균의 접촉성 리포다당류 분자상의 혈청형 결정인자와 특성적으로 반응하는 인체 단크론 항체를 분비하는 불멸변형 인체 임파세포선.
  9. 그람음성균이 엔테로박테리아세, 박테로이다세 또는 슈도모나다세과의 한 멤버인 청구범위 8에 의거한 세포선.
  10. 상기 그람 음성균이 슈도모나 에루기노자의 패셔 면역형인 청구범위 9에 의거한 세포선.
  11. A.T.C.C. 번호 CRL 8562, CRL 8752, CRL 8753, CRL 8754, CRL 8795, CRL8796또는 CRL8797의 하나인 청구범위 10에 따르는 세포선.
  12. 청구범위 1,2,3,4 또는 5항의 어느 것에 의거한 조성물의 예방제 또는 치료제 양을 포유동물의 숙주에 투여하는 것으로 이루어지는 균에 이환된 포유동물 숙주를 치료하는 방법.
  13. 균에 이환 또는 감수성인 포유동물 숙주를 치료하는 방법. 이는 청구범위 6항의 어느 것에 따르는 조성물의 상기 숙주에 대한 예방제 또는 치료학적 양을 투여하는 것으로 구성된다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850003622A 1984-05-25 1985-05-25 그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법 KR850008282A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61418484A 1984-05-25 1984-05-25
US614184 1984-05-25

Publications (1)

Publication Number Publication Date
KR850008282A true KR850008282A (ko) 1985-12-16

Family

ID=24460190

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850003622A KR850008282A (ko) 1984-05-25 1985-05-25 그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법

Country Status (16)

Country Link
US (1) US4834975A (ko)
EP (1) EP0163493B1 (ko)
JP (1) JPS6169796A (ko)
KR (1) KR850008282A (ko)
AT (1) ATE62021T1 (ko)
AU (1) AU600222B2 (ko)
DE (1) DE3582274D1 (ko)
DK (1) DK233385A (ko)
ES (1) ES8702792A1 (ko)
FI (1) FI89278C (ko)
GR (1) GR851234B (ko)
HU (1) HU202927B (ko)
IE (1) IE58411B1 (ko)
IL (1) IL75277A (ko)
NO (1) NO167758C (ko)
ZA (1) ZA853888B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
JPS61155398A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤
EP0233289B1 (en) * 1984-12-26 1993-03-10 Teijin Limited Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody
JPS61152280A (ja) * 1984-12-26 1986-07-10 Teijin Ltd 抗緑膿菌ヒト抗体を産生する形質転換細胞及びその製造法並びにその使用方法
ATE77243T1 (de) * 1985-03-11 1992-07-15 Teijin Ltd E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
EP0494085A1 (en) 1985-09-27 1992-07-08 The Regents Of The University Of California Monoclonal antibodies binding determinants of gram negative bacteria
US5179001A (en) * 1985-09-27 1993-01-12 The Regents Of The University Of California Detection and monitoring of chronic and gram-negative infection
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
ZA87863B (en) * 1986-02-07 1987-09-30 Genetic Systems Corp Cross-protective human monoclonal antibody compositions
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
ES2009365A6 (es) * 1986-04-24 1989-09-16 Univ California Procedimiento de otencion de anticuerpos monoclonales para bacterias gram-negativas.
GB8610202D0 (en) * 1986-04-25 1986-05-29 Technology Licence Co Ltd Monoclonal antibodies
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
ZA878610B (en) * 1986-11-20 1989-06-28 Minnesota Mining & Mfg Method for the evaluation of oral microbes
US5521085A (en) * 1986-12-15 1996-05-28 Mitsui Toatsu Chemicals, Inc. Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
AU1807188A (en) * 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
JPH01197500A (ja) * 1988-01-29 1989-08-09 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
JPH02283294A (ja) * 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
US5233024A (en) * 1991-04-09 1993-08-03 The Brigham & Women's Hospital Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
ES2104855T3 (es) * 1991-12-24 1997-10-16 Wako Pure Chem Ind Ltd Procedimiento para extraer endotoxinas.
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5562902A (en) * 1994-03-14 1996-10-08 Arp Biomed, Inc. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin
US5807694A (en) * 1995-09-07 1998-09-15 Economic Innovation And Technology Council, University Of Manitoba Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CA2289979C (en) * 1997-05-15 2007-02-20 Transplantation Technologies Inc. Methods of modulating immune coagulation
US6790661B1 (en) 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
WO2001061305A2 (en) * 2000-02-15 2001-08-23 Fit Biotech Oyj Plc Immunoassays detecting or making use of at least two rubber latexallergens
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
BRPI1013427A2 (pt) 2009-04-09 2016-04-05 Kenta Biotech Ag anticorpo monoclonal humano para lipopolissacarídeos (lps) de serotipo iats o1 de pseudomonas aeruginosa, hibridoma, ácido nucleico, vetor, celula hospedeira, metodo para produzir o anticorpo monoclonal humano, composição farmaceutica, uso de um anticorpo monoclonal humano, kit de teste para diagnostico de p. aeruginosa em uma amostra
US20130022604A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU530649B2 (en) * 1981-01-28 1983-07-21 Coats Patons Plc Method of manufacturing monoclonal antibodies and capable of manufacturing such antibodies
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
JPS5929622A (ja) * 1982-08-10 1984-02-16 Meiji Seika Kaisha Ltd モノクロ−ナル抗体、その製造法およびその用途
CA1262238C (en) * 1982-09-30 1989-10-10 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS
DE3484773D1 (de) * 1983-05-06 1991-08-08 Velos Group Mit endotoxinkern reaktionsfaehige monoklonale antikoerper.
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria

Also Published As

Publication number Publication date
IE851302L (en) 1985-11-25
FI89278C (fi) 1993-09-10
FI852029A0 (fi) 1985-05-21
NO167758B (no) 1991-08-26
HU202927B (en) 1991-04-29
DK233385D0 (da) 1985-05-24
ATE62021T1 (de) 1991-04-15
AU600222B2 (en) 1990-08-09
FI852029L (fi) 1985-11-26
NO167758C (no) 1991-12-04
ZA853888B (en) 1986-01-29
EP0163493A3 (en) 1986-07-02
HUT38123A (en) 1986-04-28
US4834975A (en) 1989-05-30
FI89278B (fi) 1993-05-31
IL75277A (en) 1990-02-09
ES8702792A1 (es) 1987-01-16
NO852093L (no) 1985-11-26
DE3582274D1 (de) 1991-05-02
IE58411B1 (en) 1993-09-22
JPS6169796A (ja) 1986-04-10
EP0163493A2 (en) 1985-12-04
IL75277A0 (en) 1985-09-29
AU4285885A (en) 1985-11-28
ES543474A0 (es) 1987-01-16
GR851234B (ko) 1985-07-01
EP0163493B1 (en) 1991-03-27
DK233385A (da) 1985-11-26

Similar Documents

Publication Publication Date Title
KR850008282A (ko) 그람음성균상의 혈청형 리포다당류 결정인자에 대한 인체 단크론(monoclonal)항체와 그 제조방법
BR9906287A (pt) Bactéria pertencente ao gênero escherichia e que tem uma capacidade para produzir um l-aminoácido, e, processo para produzir um l-aminoácido
KR870003793A (ko) 트롬빈 제재의 방법
KR920703071A (ko) 지질 저하제로서 콜레스티라민을 함유하는 미세정제
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
KR900001357A (ko) 착색을 방지하는 외용제
KR870002826A (ko) 퍼어머넌트 웨이브 용제
KR920006004A (ko) 헤모필루스 파라갈리나룸 (Haemophilus paragallinaum)왁찐
KR920703097A (ko) 스트렙토코커스 b군에 대한 백신 접합체
KR830005360A (ko) 키자니마이신의 제조방법
KR890008325A (ko) 아미노디옥시 만니톨의 제법
KR910015270A (ko) 침구류
KR840002239A (ko) 화장품
KR830004414A (ko) 마이코페놀산 유도체의 제조방법
SE8100623L (sv) Topiskt, indomentacinhaltigt lekemedel
KR830005357A (ko) 나라신의 제조방법
KR830004412A (ko) 밀디오 마이신의 제조법
KR930000109A (ko) 참. 존
Beckmann et al. Immunochemical investigations of antigens isolated from Bacteroides ovatus strain ATCC 8483
KR910009917A (ko) 유산균을 이용한 항 종양제
KR910017943A (ko) 어유류 산화방지법
KR950014316A (ko) 옥스갈 및 젠타마이신이 함유된 선택배지를 사용한 비피도박테리아의 생균수 측정방법
KR970010960A (ko) 점질다당류를 생산하는 새로운 유산균
KR890014727A (ko) 클로스트리듐·부티리컴의 선택 배지
KR880002975A (ko) P형 액정조성물

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application